Ultrase Related Published Studies
Well-designed clinical trials related to Ultrase (Lipase / Amylase / Protease)
An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study. [2006.08]
Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy. [2004.12]
Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. [2002.07]
A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. [2000.08]
Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis. [1996.07]
Comparison of a high lipase pancreatic enzyme extract with a regular pancreatin preparation in adult cystic fibrosis patients. [1994.12]
Comparative in vitro and in vivo studies of enteric-coated pancrelipase preparations for pancreatic insufficiency. [1993.11]
A double blind lipase for lipase comparison of a high lipase and standard pancreatic enzyme preparation in cystic fibrosis. [1993.02]
Well-designed clinical trials possibly related to Ultrase (Lipase / Amylase / Protease)
Efficacy of lower than standard doses of pancreatic enzyme supplementation therapy during acid inhibition in patients with pancreatic exocrine insufficiency. [2006.09]
The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. [2006.08]
Enteric-coated pancreatic enzyme with bicarbonate is equal to standard enteric-coated enzyme in treating malabsorption in cystic fibrosis. [2006.03]
Effect of peptide YY on pancreatico-biliary secretion in humans. [2005.08]
Combining unprotected pancreatic enzymes with pH-sensitive enteric-coated microspheres does not improve nutrient digestion in patients with cystic fibrosis. [2005.04]
Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. [2005.04]
Effects of copper-bearing montmorillonite on growth performance, digestive enzyme activities, and intestinal microflora and morphology of male broilers. [2004.11]
Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients. [2004.09.10]
Creon 10,000 Minimicrospheres vs. Creon 8,000 microspheres--an open randomised crossover preference study. [2002.12]
Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan. [2002.07]
The exacerbation of pancreatic endocrine dysfunction by potent pancreatic exocrine supplements in patients with chronic pancreatitis. [2001.04]
Digestive and bacterial enzyme activities in broilers fed diets supplemented with Lactobacillus cultures. [2000.06]
Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. [1999.07]
The effect of pancreatic enzyme supplementation in patients with steatorrhoea after total gastrectomy. [1999.03]
Influence of high-dose pancreatic enzyme treatment on pancreatic function in healthy volunteers. [1998.04]
Assessment of the effectiveness of drug therapies on nutritional status in the elderly: "concerning a randomised, double-blind clinical study of the activity of pancreatic extracts and a placebo during the renutrition of elderly subjects suffering from protein caloric undernutrition". [1998]
Effect of acute hyperglycaemia on basal and fat-induced exocrine pancreatic secretion in humans. [1997.12]
M1-muscarinic mechanisms regulate interdigestive cycling of motor and secretory activity in human upper gut. [1996.10]
Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group. [1996.09.26]
Pancreatic enzyme supplementation in acute pancreatitis. [1995.06]
Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy. [1994.05]
[Comparative clinical study of Neopanpur and Creon] [1994.01.02]
High dose Nutrizym 22 in cystic fibrosis. [1993.09]
A comparison of two pancreatin microsphere preparations in cystic fibrosis. [1992.03.25]
Feedback regulation of stimulated pancreatic enzyme secretion during intraduodenal perfusion of trypsin in man. [1988.06]
Efficacy of pancreatic enzyme supplementation in children with cystic fibrosis: comparison of two preparations by random crossover study and a retrospective study of the same patients at two different ages. [1988]
Other research related to Ultrase (Lipase / Amylase / Protease)
[Isolation of pancreatic lipase activity-inhibitory component of spirulina platensis and it reduce postprandial triacylglycerolemia] [2006.01]
Ultrase and Viracept. [1999.10]
Treatment failure after substitution of generic pancrelipase capsules. Correlation with in vitro lipase activity. [1990.05.09]
Increase in pancreatic lipase and trypsin activity and their mRNA levels in streptozotocin-induced diabetic rats. [1989.08]
Diagnostic value of immunoreactive phospholipase A2 in acute pancreatitis. [1989.02.01]
An enzyme immunoassay for the determination of lipase in human duodenal fluid. [1989]
Other possibly related research studies
[The role of orlistat in the treatment of obesity] [2005.03.13]
Skin prick test reactivity to supplemental enzymes in cystic fibrosis and pancreatic insufficiency. [2005.02]
The secretagogue effect of the poison from Centruroides limpidus limpidus on the pancreas of mice and the antagonistic action of the Bouvardia ternifolia extract. [2005.01]
Fibrosing colonopathy in an adult cystic fibrosis patient after discontinuing pancreatic enzyme therapy. [2004.09]
A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. [2004.10.01]
The enzyme levels in blood are not affected by oral administration of a pancreatic enzyme preparation (Creon 10,000) in pancreas-insufficient pigs. [2004.01]
Selective decreases in amphetamine self-administration and regulation of dopamine transporter function in diabetic rats. [2003.02]
Pancreatic metallothionein-I may play a role in zinc homeostasis during maternal dietary zinc deficiency in mice. [2003.01]
The development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: implications for clinical care, recognition and management. [2002.12]
Pancreatic toxicity after liposomal amphotericin B. [2002.06]
Postcibal gastric emptying of pancreatin pellets: effects of dose and meal oil. [2001.09]
Efficacy of oral pancreatic enzyme therapy for the treatment of fat malabsorption in HIV-infected patients. [2001.10]
Pancreatic enzyme replacement therapy. [2001.04]
Defective dietary fat processing in transgenic mice lacking aquaporin-1 water channels. [2001.01]
Diet stimulation as a synergistic factor of aggravation in a pancreatic bile duct ligation-induced rat pancreatitis model. [2000.11]
Comparison of two enteric coated microsphere preparations in the treatment of pancreatic exocrine insufficiency caused by cystic fibrosis. [2000.06]
Acquired segmental megacolon in an adult patient with cystic fibrosis. [2000.02]
Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. [1999.11]
Enzymatic therapy in patients with chronic pancreatitis. [1999.09]
Colonic wall thickness, pancreatic enzyme dose and type of preparation in cystic fibrosis. [1998.10]
Faecal bile acid and dietary residue excretion in cystic fibrosis: age group variations. [1998.09]
Effects of pancreatic enzyme preparations on erythrocyte glutathione peroxidase activities and plasma selenium concentrations in cystic fibrosis. [1998.07.15]
Mismatch of duodenal deliveries of dietary fat and pancreatin from enterically coated microspheres. [1997.10]
Is fibrosing colonopathy an immune mediated disease? [1997.07]
13Carbon mixed triglyceride breath test and pancreatic enzyme supplementation in cystic fibrosis. [1997.04]
Response to a single oral dose of all-rac-alpha-tocopheryl acetate in patients with cystic fibrosis and in healthy individuals. [1996.05]
[Differential therapy of exocrine pancreatic insufficiency--current aspects and future prospects of substitution therapy with pancreatic enzymes] [1995.12]
Gut inflammation in children with cystic fibrosis on high-dose enzyme supplements. [1995.11.11]
Fibrosing colonopathy in cystic fibrosis: results of a case-control study. [1995.11.11]
Faecal interleukin-8 and tumour necrosis factor-alpha concentrations in cystic fibrosis. [1995.07]
Chronic metabolic alkalosis: not uncommon in young children with severe cystic fibrosis. [1995]
Pancolonic disease in cystic fibrosis and high-dose pancreatic enzyme therapy. [1994.10]
Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. [1994.01.08]
[Long-term treatment of mucoviscidosis. Results with a microencapsulated pancreatic enzyme preparation] [1993.02.10]
Chronic pancreatitis. [1993.02]
Comparison between a standard pancreatic supplement and a high enzyme preparation in cystic fibrosis. [1992.10]
Postoperative management of patients with total exocrine pancreatic insufficiency. [1990.06]
Unclogging feeding tubes with pancreatic enzyme. [1990.03]
Effect of pancreatic enzyme supplements on iron absorption. [1989.08]
Pancreatic enzyme replacement therapy. Importance of gastric acid secretion, H2-antagonists, and enteric coating. [1989.03]
Pancreatic enzyme replacement therapy in post-pancreatectomy patients. [1989]
Correction of malnutrition and maldigestion with enzyme supplementation in patients with surgical suppression of exocrine pancreatic function. [1988.12]
Duodenal instillation of pancreatin does not abolish steatorrhea in patients with pancreatic insufficiency. [1988.10]
Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis. [1988.10]
Use of pancreatic Schilling test to determine efficiency of pancreatic enzyme delivery in pancreatic insufficiency. [1988.10]
The management of enzymatic therapy in cystic fibrosis patients by an individualized approach. [1988]
Malabsorption in cystic fibrosis: mechanisms and treatment. [1988]
Efficacy of pancrease: crossover comparative study versus eurobiol in cystic fibrosis. [1988]
In vivo and in vitro studies of microsphere pancreatic supplements. [1988]
Characterization of aeromonads isolated from the river Narmada, India. [2005]
Prophylactic pancreatic enzymes to reduce feeding tube occlusions. [2003.10]
Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. [2005]
Production of bacteriocin-like inhibitory compounds by human fecal Bifidobacterium strains. [2005.05]
Selected biochemical parameters and ultrastructural picture of pancreas due to Ulinastatin treatment of experimental acute pancreatitis. [2005.03]
Effect of early feed restriction and enzyme supplementation on digestive enzyme activities in broilers. [2004.09]
Three-day enteral exposure to a red kidney bean lectin preparation enhances the pancreatic response to CCK stimulation in suckling pigs. [2005]
Influence of whole wheat and xylanase on broiler performance and microbial composition and activity in the digestive tract. [2004.06]
Calpain I inhibitor ameliorates the indices of disease severity in a murine model of cerulein-induced acute pancreatitis. [2004.08]
The effects of protease supplementation on skeletal muscle function and DOMS following downhill running. [2004.04]
Evaluation of serum values of pancreatic enzymes after endoscopic retrograde pancreatography in dogs. [2004.05]
Effect of intraduodenal administration of ursodeoxycholic acid on interdigestive interaction between gallbladder motility, pancreatic secretion and endocrine activity. [2004]
|
